Introduction
Gene therapy is a new option for treatment of heart failure (HF). Several gene therapies have been developed to improve cardiac performance in HF models by targeting calcium and adrenergic signalling, including the overexpression of sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA2a) which regulates calcium movement between the cytoplasm and the sarcoplasmic reticulum (SR), 1 -3 S100A which modifies SR calcium handling, 4, 5 -adrenergic receptor kinase ( -ARKct) which restores -adrenergic receptor signalling, 6, 7 small ubiquitin-related modifier 1 (SUMO-1) which regulates SERCA2a through post-transcriptional modification, 8 and an inhibitor of protein phosphatase 1 (I-1c) which regulates de-phosphorylation of phospholamban. 9, 10 All of these gene therapies have employed adeno-associated virus (AAV) vectors to deliver their respective transgene. SERCA2a (Mydicar) is the most advanced of these gene therapies, and a clinical trial has shown that it mediates beneficial effects on cardiac function as well as a decrease in hospitalizations.
11,12
In this study, we sought to develop ribonucleotide reductase (RNR) gene therapy, which, in contrast to the above-mentioned therapies, is independent of calcium and adrenergic signalling and instead works to increase contractility directly by producing 2-deoxy-ATP (dATP) for myosin activity. Overexpression of RNR represents an entirely novel gene therapy concept for HF, where the gene product does not, in itself, produce the therapeutic effect. RNR is an essential enzyme that catalyses the de novo synthesis of deoxyribonucleotide triphosphates (dNTPs), used principally for DNA synthesis and repair. The enzyme is a heterotetramer of two subunits, Rm1 and Rm2. 13 Regnier et al. have demonstrated that small elevations of cytoplasmic levels of dATP increase force generation, cross-bridge cycling, and calcium sensitivity in skinned rat cardiomyocytes, 14, 15 and in myocardium from failing human hearts. 16 These results
were obtained with increases in dATP concentration as small as ∼1.5% of the total ATP nucleotide pool. Our group has shown that overexpression of RNR in rat cardiomyocytes, 17 7 BB-R12 or sham control was administered at 2 weeks post-MI (day 0) in an unblinded manner at 1 × 10 13 , 5 × 10 12 , and 1 × 10 12 viral genome (VRG), hereafter referred to as high, medium, and low doses, respectively. Two-thirds of the study drug volume was infused antegradely into the left main coronary artery and the remainder into the proximal right coronary artery. Echocardiography, haemodynamics, animal wellness, pathology, immune response, and biomarkers were assessed as shown in Figure 1 . The timing of the cardiac assessments was based on results of prior rodent cardiac performance studies conducted in our laboratory. All values are reported as the mean ± standard error of the mean (SEM). Data were analysed mainly by a mixed effects regression model with factors for treatment group and time.
Results

Swine myocardial infarction-heart failure model
The experimental design and flow of animals through the study is shown in Figure 1 . Yucatan minipigs (35-45 kg) were screened for neutralizing antibodies to AAV6, and a total of 28 seronegative animals were enrolled in this study and underwent MI induction (Day −14). Eight pigs died from ventricular fibrillation during the MI induction procedure, and an additional three pigs died after MI induction but prior to administration of BB-R12 gene therapy or placebo. A total of 17 pigs received intracoronary infusions of BB-R12 or formulation buffer (sham) as shown in Table 1 . All treated animals survived until euthanasia at 56 days post-treatment.
Effect of BB-R12 on cardiac systolic function
The mean values for each group and time point are shown in Table 1 . All four groups had comparable LVEF prior to infarction. By 14 days post-MI, mean LVEF had declined significantly in all groups, though the magnitude of the decline was variable. In the sham group, LVEF continued to decline at 56 days post-saline treatment ( Table 1 ; Figures 2A and 3A) . In contrast, LVEF in the high-dose group recovered after BB-R12 treatment at 28 and 56 days post-treatment (P = 0.04 and P = 0.006 vs. control at each time, respectively). Interestingly, the medium-dose group did not respond at 28 days, but recovered at 56 days post-treatment and LVEF was then significantly higher than in the sham group (P = 0.03) ( Figure 3A) . The low-dose group showed no improvement from the time of gene delivery to 56 days.. The change of LVEF from day 0 to 56 was +7% absolute EF units for the high-dose group compared with −10% for the sham group (P < 0.05) ( Figures 2B and 3B ). An exploratory post-hoc analysis took into account the model variability in baseline cardiac function, presumably related to differences in infarct size. All active-treated animals were pooled, then Figure 2C ). The sham-treated group showed significant deterioration of LVEF from Day 0 to Day 56 (P = 0.02). The group with high severity HF showed significant improvement in LVEF at Day 56 (P = 0.001) and a trend towards improvement at Day 28 (P = 0.08), as well as a significant improvement compared with the sham-treated group (P = 0.02), while the low severity HF group showed no change from Day 0 to Day 56 and no difference from control.
Similar findings occurred for the related measures of LV fractional shortening (LVFS). While the sham and low-dose groups showed a decline in LVFS at 56 days post-administration, both the high-and medium-dose groups showed increases ( Figure 3C ). At 56 days post-treatment, LVFS for the high-dose group showed a +7% increase, relative to the Day 0 function, compared with a −5% decrease in the sham group. LVFS in the high-dose group was significantly higher than in the sham group at 56 days after treatment (P = 0.01).
BB-R12 effect on left ventricular dimensions
In all groups, LV end-systolic dimension (LVESD) increased from pre-infarction to the time of treatment at Day 0 ( Figure 4A Figure 4B ). In the high-and medium-dose treated groups, however, the LVESD at 56 days post-treatment was similar to or smaller then that at Day 0. In the high-dose treated group, LVESD at 56 days post-treatment was significantly shorter than in the sham group (P = 0.01, Table 1 ), reflecting enhanced contractility. In contrast, LV end-diastolic dimension (LVEDD) showed progressive dilation during 56 days after gene delivery for all groups ( Figure 4C ). There was no significant difference in LVEDD between the sham and treated groups at 56 days after treatment, indicating comparable LV remodelling.
BB-R12 effects on +dP/dt, −dP/dt, and end-diastolic pressure
The mean values for haemodynamic measurements are shown in Table 1 . At 14 days following MI (Day 0), the mean values of the maximum rate of pressure rise (+dP/dt), a parameter of systolic function, maximum rate of pressure decline (−dP/dt), a parameter of early diastolic function, and LV end-diastolic pressure (LVEDP) showed changes consistent with the onset of HF in all groups, and these changes persisted in the sham group. At 56 days after treatment, there was improvement in these measures in the highand medium-dose treated groups compared with the sham group, although there was no difference in blood pressure and heart rates ( Figure 5 ). The mean change in + dP/dt from Day 0 to 56 was significantly increased in the high-dose group compared with Data are shown as mean ± SEM. * P < 0.05. ** P < 0.01 for differences between the sham group and each of the other groups, mixed effects regression model with factors for dosing group and time.
the sham group, reflecting the positive inotropic effect of BB-R12 (P = 0.004, Figure 5A and B). There were similar improvements in the negative rate of pressure change (−dP/dt) in response to BB-R12 treatment ( Figure 5C and D) . The mean LVEDP increased at 14 days following MI in all groups, which persisted in the sham and . . . . . . . . . . . . . low-dose treated groups. In the high-and medium-dose treated groups, MI-induced increases in LVEDP were reversed at Day 56 following treatment with BB-R12 ( Figure 5E and F) . The LVEDP change from Day 0 to 56 was significantly improved in the high-dose group compared with the sham group (P = 0.04, Figure 5F ). The other measured haemodynamic parameters such as pulmonary capillary wedge pressure, pulmonary arterial pressure, central venous pressure, and cardiac output in the treated groups were not significantly different from the sham group after 56 days (Supplementary material online, Table S1 ).
BB-R12 does not evoke a significant humoral or cellular immune response
The development of a humoral immune response was monitored using an enzyme-linked immunosorbent assay (ELISA) for the viral capsid protein. Titres of anti-AAV6 antibodies are shown in Supplementary material online, Table S2 . Most samples contained no appreciable antibody levels above the minimum detectable level (<1:800). In some treated animals at some time points, there was a transient and unremarkable titre of 1:800. 
Effects of BB-R12 on blood counts, chemistries, or biomarkers
There were no significant differences between sham and treated groups in clinical pathology at 14, 28, or 56 days after gene delivery. The results of this analysis suggest no adverse effects on blood composition, blood chemistry, or liver enzymes following BB-R12 treatment. Sporadic elevations of serum troponin were observed Table S4 ).
Pathology and biodistribution
Overall, MI led to similar lesions in the heart in all of the test groups and the sham control group. The percentage of fibrosis in the central infarct area in the sham and treated groups was similar (Supplementary material online, Figure S1 ). The severity, frequency, and distribution of the lesions in the treated hearts were similar to those seen in the sham group. There were no organ lesions or histopathological changes in the treatment groups attributed to the BB-R12 therapy. No significant findings were observed by animal wellness monitoring across all treatment groups from the gene delivery to the endpoint. There was no significant difference in the mean AAV copy number per microgram of DNA in the heart (left ventricle, left atrium, and right ventricle), lung, and liver between the treated groups, though the number of tissue samples analysed was small (Supplementary material online, Figure S2) . No viral DNA was detected in the sham group.
Discussion
In this pilot study, we observed persistent improvement in cardiac BB-R12 in a swine MI-HF model. Our findings at 2 months following therapy included (i) improvements in LVEF, LVFS, and LVESD; (ii) improvements in haemodynamic measurements including + dP/dt, −dP/dt, and LVEDP; and (iii) no safety or toxicological concerns were observed. The small number of study animals and inherent variability of the porcine MI-HF model limit the conclusions that can be drawn, but consistent improvements across multiple measures of cardiac performance, especially in the animals with the most severe HF, are encouraging. Thus, these findings extend our previous observations in rodent and ex vivo experiments to a standard large-animal model of HF. Gene therapies that are in development involve manipulation of either calcium handling (e.g. SERCA2a) or calcium indirectly via adrenergic signalling, and have been reported to improve HF in large-animal models.
1 -10 In this study, we observed improvement in multiple key contractile parameters in a large-animal MI-HF model using a gene therapy that works via a very different mechanism, cardiac myosin activation via cardiac-specific elevation of cytosolic dATP. Our group has shown that small amounts of dATP catalyse enhanced cardiac performance through myosin activation. 14 -16 The mechanism involves facilitation of actin-myosin cross-bridge cycling. Faster cycling allows more myosin heads (the force generators) to interact with actin during each cardiac contraction. Enhanced contractility has been seen across the range of physiological levels of calcium (enhanced calcium sensitivity), but dATP has no effect on calcium transients.
15,17
The increase in dATP is achieved through the enhanced expression of RNR, which is normally down-regulated in mature cardiac muscle cells, and the increased expression of which results in the synthesis of dATP in cardiomyocytes. Though not measured directly in this pilot study, we have previously demonstrated that up-regulation of RNR is linked to increased dATP levels and this, in turn, to enhanced cardiac performance. 17 Expression of RNR using the cTnT promoter facilitates cardiomyocyte-specific transcription and minimizes possible off-target effects with a level of therapeutic specificity not achievable using small molecule drugs or gene therapies using constitutively expressed regulatory elements. Interestingly, even though contraction is stronger and faster, chemo-mechanical modelling suggests that the weaker hydrostatic interaction between dATP and myosin in the binding pocket (vs. ATP) may result in a faster release of the hydrolysis product dADP, thus the myosin detachment rate and relaxation is also faster. 20 Consequently, the kinetics of cell, tissue, and organ relaxation appear matched to the enhanced contractility. This is important, because an inotrope that impairs relaxation would offer substantially less benefit due to increased end-diastolic pressure and pulmonary congestion.
Direct targeting of the contraction machinery of the cardiac muscle cell by intracellular production of a superior myosin substrate is a new therapeutic paradigm to treat HF and is . . independent of both calcium and adrenergic signalling. Omecamtiv, a small molecule drug in clinical development, represents a new class of inotropic agents, cardiac myosin activators. 21 Omecamtiv works directly on myosin and stimulates myocardial ATPase by strengthening myosin-actin cross-bridge formation, thus increasing LV systolic function independent of calcium while decreasing filling pressure without increasing the heart rate or oxygen consumption. 22, 23 Omecamtiv has reached later stage clinical testing, which validates myosin activation as a target for inotropic therapy. However, omecamtiv is delivered by repeated i.v. infusions or chronic oral dosing, does not appear to affect the rate of ventricular pressure development, and increases systolic ejection time in a dose-dependent manner, leading to the shortening of diastole. 22 In contrast dATP and BB-R12 requires a one-time administration, and appears to increase LV function with no prolongation of systolic ejection time or shortening of diastole.
Gene therapy using BB-R12 increases cardiac function by turning a small number of transduced cardiomyocytes into cellular factories that generate dATP. dATP increases the contraction of both the transduced cell and adjacent cardiac muscle cells by passive diffusion of the nucleotide throughout the heart via gap junctions. Lundy et al. showed that small numbers of ex vivo RNR-infected cardiomyocytes directly injected into three loci in rat hearts had positive overall effects on cardiac function, demonstrating that a small proportion of transduced cells distributed in a limited number of sites can increase cardiac function. 19 This amplification of the effect of RNR up-regulation may indicate that the number of transduced cells required to produce a therapeutic effect may be lower than for other gene therapies. We speculate that the delayed time course of improvement of cardiac performance observed in the medium-dose treated group may be consistent with the gradual accumulation of cytosolic dATP over time. In previous rodent and ex vivo experiments, observed increases in contractility affected the entire heart. However, the potential risks of inducing regional increases in contractility warrant further assessment. In this small, pilot study, no adverse effects of BB-R12 therapy were observed. No treatment-related deaths or adverse events were observed, and gross pathology and histopathology showed no difference from sham-treated animals. Blood chemistry was unremarkable and no elevation of liver enzymes was observed. are identical between pigs and humans and therefore these results are reassuring that a cellular immune response to the transgene product was unlikely. Nowakowski et al. studied transgenic mice that expressed RNR constitutively in all cells, and observed no documentable cardiac pathology (hypertrophy, fibrosis, etc.), but found a marked, lifelong increase in cardiac performance. 18 Based on this work, we expected that cardiac-specific transgene expression would probably produce a safe therapeutic. Our pilot study observations are consistent with this expectation. It should be noted that RNR is regulated allosterically by dATP, and additional post-translational regulatory mechanisms also play a role, working collectively to keep dATP levels low. 13, 24 The build up of abnormal levels of dATP is further limited by the passive diffusion out of the producer cells and into adjacent coupled cells through gap junctions. However, small maximal amounts of dATP (<10% of the total ATP pool) show increases in force development and cell contraction at the myofibril level.
Study limitations
Despite the encouraging results, there are important limitations of the current pilot study that can be addressed in subsequent studies to assess further the therapeutic potential for BB-R12 in the treatment of HF. Our observations must be considered preliminary until confirmed by subsequent additional research. The timing of BB-R12 administration following MI and the timing of serial assessments in our study may not be predictive of other situations and longer term follow-up. The results from this model of recent-onset ischaemic HF may not be predictive of established ischaemic HF or other forms of HF. The doses tested and delivery protocol used were selected empirically based on our prior work and similar published studies. Further studies may provide information on optimization of dose, delivery, efficacy, and safety. We did not use continuous ECG recordings to monitor for arrhythmias, but there were no animal deaths following gene therapy. We did not measure myocardial oxygen consumption or coronary blood flow, and these should be assessed as part of further safety assessments. The neurohormonal effects of BB-R12, i.e. on BNP and catecholamine levels, should be evaluated in future experiments. Lastly, more extensive evaluation of viral and transgene persistence and expression in the heart and other organs will be needed as part of further safety evaluations.
Conclusion
Results from transgenic animals and small-animal studies have shown that overexpression of RNR in the heart leads to improved cardiac performance via synthesis of dATP. The current study extends these observations to a relevant, standard large-animal model of HF with encouraging preliminary results. We recorded persistent improvement in multiple measures of HF severity after a single treatment with BB-R12 with no observed adverse effects. As the first gene therapy with a mechanism of action that is independent of calcium regulation, these findings justify further evaluation of the therapeutic potential of BB-R12 to treat HF.
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